CHURCH OF PEPTIDES / THE 60-SECOND GUIDE

Tesamorelin

Approved human use · product-specific labels.



Guide prepared November 13, 2026 · profile review dates retained

KEEP IN MIND Evidence applies to the studied formulation, route, population and outcome—not every product sharing a name.

01 What is it?

Tesamorelin stimulates the growth-hormone-releasing hormone pathway. Its approved role is to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, a specific indication that does not make it a general weight-loss medicine. [1]

02 Potential benefits

FDA-approved to reduce excess abdominal fat in adults with HIV and lipodystrophy. Stimulates endogenous growth hormone through the GHRH receptor. The demonstrated benefit is indication-specific—not general weight management. [1]

03 Evidence & its limits

The label states that long-term cardiovascular safety has not been established and that the medicine is not indicated for weight-loss management. Elevated IGF-1, glucose intolerance or diabetes, fluid retention, and malignancy-related precautions make the narrow indication essential context. [1]

04 Risks & unknowns

Can cause glucose intolerance, elevated IGF-1, fluid retention, joint or muscle symptoms, and injection-site reactions. Hypersensitivity can occur; the label includes contraindications and pregnancy warnings. Long-term cardiovascular safety has not been established. [1]

05 Status & scope

Its approved role is to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, a specific indication that does not make it a general weight-loss medicine. [1]

06 The question to ask

Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.

SOURCES / Tap a reference to open

[1] Full evidence record, references and review dates
[2] Current FDA label
[3] FDA summary review
[4] Theratechnologies history

Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.